放化疗联合抗血管形成药靶向治疗非小细胞肺癌的临床研究  

Clinical study of radiotherapy and chemotherapy combined with antiangiogenic agents in the targeted treatment of non-small cell lung cancer

作　　者：范锋 崔鸿 崔峰 FAN Feng;CUI Hong;CUI Feng(Zoucheng Hospital of Traditional Chinese Medicine,Shandong province,Zoucbeng,Shandong,273500,China;Zoucheng People's Hospital,Shandong province,Zoucheng.Shandong,273500,China;Zoucheng Gangshan Community Health Service Center,Shandong province,Zoucheng,Shandong,273599,China)

机构地区：[1]山东省邹城市中医院,山东邹城273500 [2]邹城市人民医院,山东邹城273500 [3]邹城市钢山社区卫生服务中心,山东邹城273599

出　　处：《当代医学》2022年第13期96-99,共4页Contemporary Medicine

摘　　要：目的探讨放化疗联合抗血管形成药靶向治疗非小细胞肺癌患者的临床疗效。方法选取2017年1月至2020年12月山东省邹城市中医院收治的70例非小细胞肺癌患者作为研究对象,采用随机抽签法分为单一治疗组和联合治疗组,各35例。单一治疗组采用放化疗治疗,联合治疗组在对照组基础上联合抗血管形成药靶向治疗,比较两组患者疾病控制率、疾病缓解率、毒副反应(胃肠道反应、骨髓抑制、肝肾功能损伤、放射性损伤)发生率。结果联合治疗组疾病控制率(94.29%)、疾病缓解率(62.86%)均高于单一治疗组的(71.43%、37.14%),差异有统计学意义(P<0.05)。两组胃肠道反应、骨髓抑制、肝肾功能损伤、放射性损伤发生率比较差异无统计学意义。结论放化疗+抗血管形成药靶向治疗非小细胞肺癌效果较好,可提升疾病控制率和缓解率,且不增加胃肠道反应、骨髓抑制、肝肾功能损伤、放射性损伤发生率,可有效提升非小细胞肺癌患者整体预后水平。Objective To investigate the clinical effect of targeted therapy with radiotherapy and chemotherapy plus antiangiogenesis agents in patients with non-small cell lung cancer.Methods A total of 70 patients with non-small cell lung cancer admitted to Zoucheng Hospital of traditional Chinese medicine in Shandong Province from January 2017 to December 2020 were selected as the research subjects,and they were divided into single treatment group and combined treatment group according to random lottery method,with 35 cases in each group.The single treatment group was treated with radiotherapy and chemotherapy,and the combined treatment group was combined with targeted therapy of antiangiogenic drugs on the basis of the control group,the disease control rate,disease remission rate and incidence of toxic and side effects(gastrointestinal reaction,bone marrow suppression,liver and kidney function injury,and radiation injury)were compared between the two groups.Results The disease control rate(94.29%)and remission rate(62.86%)in the combined treatment group were higher than those in the single treatment group(71.43% and 37.14%),and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of gastrointestinal reaction,bone marrow suppression,liver and kidney function injury and radiation injury between the two groups.Conclusion Radiotherapy and chemotherapy combined with antiangiogenic drugs in the targeted treatment of NSCLC is effective,which can improve the disease control rate and remission rate without increasing the incidence of gastrointestinal reaction,bone marrow suppression,liver and kidney function injury and radiation injury,and effectively improve the overall prognosis of NSCLC patients.

关 键 词：非小细胞肺癌 放化疗 抗血管形成药 靶向治疗 疾病控制率 毒副反应 

分 类 号：R734.2[医药卫生—肿瘤]